Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 1/2 8Phase 3 6Phase 4 4Phase 1 4Phase NA 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 123Terminated 27Active not recruiting 6Withdrawn 4Unknown 4Not yet recruiting 3Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Bortezomib × Clear all
NCT05982756 2023-08-09

Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

Zhongnan Hospital

Phase 1 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 1 Unknown
60 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02955810 2018-03-29

CyBorD-Dara

National University of Ireland, Galway, Ireland

Phase 1 Unknown
18 enrolled
Plasma cell

Multiple Myeloma

NCT01439750 2017-08-07

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

Milton S. Hershey Medical Center

Phase 1 Unknown
13 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡